MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, September 25, 2013

Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS

September 23, 2013
 More than 55 company-sponsored presentations underscore Biogen Idec's commitment to treatment advances for people with MS --
- Company will also launch Registry Research Fellowship Programme -
WESTON, Mass.--(BUSINESS WIRE)--September 23, 2013-- 
Biogen Idec (NASDAQ: BIIB) will present 58 data sets from the company's multiple sclerosis (MS) clinical portfolio of approved and investigational products at the 29(th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5.
The collection of data being presented at ECTRIMS represents Biogen Idec's industry-leading expertise in MS research and showcases the company's deep understanding of differing patient needs. Through decades of cutting-edge science, Biogen Idec has more experience than any other company in advancing the treatment of this disease, recognising that physicians need therapeutic choices to meet treatment goals.
"Biogen Idec is proud to be at the forefront of innovation in MS, which has been made possible through our research and development efforts over the past 30 years," said Douglas E. Williams, Ph.D., executive vice president, Research and Development at Biogen Idec. "Our commitment has enabled us to bring a number of therapy options to patients, and we are excited to be presenting data on some promising candidates which have the potential to broaden the treatment spectrum for people living with this chronic, debilitating disease."
Data at ECTRIMS will be presented from across Biogen Idec's portfolio, including:
Approved medicines:
TYSABRI(R) (natalizumab): offers established efficacy that has been proven to reduce relapses and slow disability progression.
TECFIDERA(R) (dimethyl fumarate): an oral treatment for relapsing forms of MS, including relapsing-remitting MS (RRMS), which has been clinically proven to significantly reduce important measures of disease activity with a favorable safety/tolerability profile. TECFIDERA is currently approved in the United States, Canada and Australia.
FAMPYRA(R) (prolonged-release fampridine tablets): the first approved treatment to address the unmet medical need of walking improvement in MS patients, demonstrating efficacy in patients with all MS types. Approved in the European Union.
Investigational medicines:
PLEGRIDY(TM) (pegylated interferon beta-1a): a potential new molecular entity for relapsing forms of MS in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body. Pegylation offers a less-frequent dosing schedule.
DACLIZUMAB HIGH-YIELD PROCESS (DAC HYP): is being developed as a once-monthly subcutaneous injection. DAC HYP is believed to target the activated immune cells that can play a key role in MS without causing general immune cell depletion. DAC HYP is being developed under a collaboration agreement with AbbVie, Inc.
Anti-LINGO-1 (BIIB033): is the first candidate being investigated for its potential to repair neurons damaged by MS.
Registry Research Fellowship Program opening for applications
At ECTRIMS, Biogen Idec will also launch The Multiple Sclerosis Registry Research Fellowship Program, an initiative which solidifies our ongoing commitment to clinical research in order to improve the lives of people living with MS. Grants awarded through the program will provide an annual stipend of up to EUR75,000 per fellow, for training in research with large real-world evidence datasets in MS.
Full session details of the 2013 Annual Meeting can be found on the ECTRIMS website:
The titles of key Biogen Idec abstracts are as follows:


To comment - click the comment link shown below
USE OUR SHARE LINKS at the top of this page  - to provide this article to others
REMAIN up to date with MS News and Education
Visit:  to register

No comments: